Home > Insider Trading > Filing (0001209191-21-058061)

Filing Details

Accession Number:: 0001209191-21-058061
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-29 16:39:15
Reporting Period:: 2021-09-27

Accepted Time:: 2021-09-29 16:39:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1664710	Keros Therapeutics Inc.	KROS	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1808365	Julius Knowles	C/O Keros Therapeutics, Inc. 99 Hayden Avenue, Suite 120, Building E Lexington MA 02421		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-27	27,373	$40.51	487,249	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-27	17,854	$40.51	327,731	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-27	20,292	$41.52	466,957	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-27	13,233	$41.52	314,498	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-27	10,018	$42.29	456,939	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-27	6,532	$42.29	307,966	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6).
The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.96 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.93 inclusive.